Julius Knowles

Julius Knowles (senior executive) discloses dealings in Keros Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 13 April 2020 to 21 November 2025, the count stands at 14 filings.

The open-market side counts 1 purchase for €23k alongside 11 sales for €2.8M. The net balance comes to €2.8M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant.

The newest entry dates from 18 December 2025: a transaction of €2.9M, in Keros Therapeutics, Inc. The latest purchase dates back some time: it was published 1,367 days ago, on 20 January 2023. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.